Ericka B Trarbach1, Alexander A Jorge2, Felipe H Duarte3, Marcello D Bronstein3, Raquel S Jallad3. 1. Laboratory of Cellular and Molecular Endocrinology - LIM25, Clinical Hospital of the University of São Paulo Medical School, Av Dr Arnaldo, 455, 4 andar, sala 4345, São Paulo, SP, CEP: 01246-903, Brazil. ericka.trarbach@hc.fm.usp.br. 2. Laboratory of Cellular and Molecular Endocrinology - LIM25, Clinical Hospital of the University of São Paulo Medical School, Av Dr Arnaldo, 455, 4 andar, sala 4345, São Paulo, SP, CEP: 01246-903, Brazil. 3. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinical Hospital of the University of São Paulo Medical School, Av Dr Eneas de Carvalho Aguiar, 155, PAMB, 8 andar, São Paulo, SP, CEP: 05403-010, Brazil.
Abstract
PURPOSE: Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. METHODS: Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays. A total of 186 patients (116 women, age range 26-88 years) were evaluated. RESULTS: No association of SOCS2 genotypes was observed with none of the following clinical and laboratorial characteristics: age, sex, body mass index, comorbidities, basal GH, oral glucose tolerance test GH nadir, IGF-I, ULNR-IGF-I. CONCLUSION: Despite of the key role of SOCS2 in the regulation of GH receptor signaling, we did not find any significant association between SOCS2 polymorphisms and acromegaly.
PURPOSE:Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. METHODS: Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays. A total of 186 patients (116 women, age range 26-88 years) were evaluated. RESULTS: No association of SOCS2 genotypes was observed with none of the following clinical and laboratorial characteristics: age, sex, body mass index, comorbidities, basal GH, oral glucose tolerance test GH nadir, IGF-I, ULNR-IGF-I. CONCLUSION: Despite of the key role of SOCS2 in the regulation of GH receptor signaling, we did not find any significant association between SOCS2 polymorphisms and acromegaly.
Authors: Daniel F Gudbjartsson; G Bragi Walters; Gudmar Thorleifsson; Hreinn Stefansson; Bjarni V Halldorsson; Pasha Zusmanovich; Patrick Sulem; Steinunn Thorlacius; Arnaldur Gylfason; Stacy Steinberg; Anna Helgadottir; Andres Ingason; Valgerdur Steinthorsdottir; Elinborg J Olafsdottir; Gudridur H Olafsdottir; Thorvaldur Jonsson; Knut Borch-Johnsen; Torben Hansen; Gitte Andersen; Torben Jorgensen; Oluf Pedersen; Katja K Aben; J Alfred Witjes; Dorine W Swinkels; Martin den Heijer; Barbara Franke; Andre L M Verbeek; Diane M Becker; Lisa R Yanek; Lewis C Becker; Laufey Tryggvadottir; Thorunn Rafnar; Jeffrey Gulcher; Lambertus A Kiemeney; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2008-04-06 Impact factor: 38.330
Authors: Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu Journal: Pituitary Date: 2012-12 Impact factor: 4.107
Authors: Raquel S Jallad; Ericka B Trarbach; Felipe H Duarte; Alexander A L Jorge; Marcello D Bronstein Journal: Pituitary Date: 2015-10 Impact factor: 4.107
Authors: M L Hartman; J D Veldhuis; M L Vance; A C Faria; R W Furlanetto; M O Thorner Journal: J Clin Endocrinol Metab Date: 1990-05 Impact factor: 5.958
Authors: Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958